On October 22, 2019, Biogen announced the positive result of its EMERGE clinical trial (in which the UDIC has participated) that has evaluated Aducanumab (an anti-alpha synuclein monoclonal antibody) in early Alzheimer’s disease. Efficacy in slowing cognitive impairment was demonstrated (measured with the CDR-SB, MMSE, ADAS-cog and ADCS-ADL scales) and a reduction in amyloid load detected in PET (almost 80%). The most frequent side effects were cerebral edema (asymptomatic and transient, in general, detected in brain MRI) and headache.These data suport the amyloid hypothesis in this disease and a change in its diagnostic and therapeutic paradigm.
